Procter & Gamble Health, a company in the Pharmaceuticals industry, reported revenue of ₹382 crore and net profit of ₹112 crore for the September 2026 quarter.
Procter & Gamble Health (NSE: PGHL) closed at ₹5,589.50 on 20 Nov 2026, down 2.5% over the past year. Its market capitalisation is ₹9,278 crore and it trades at 26.1 times earnings.
Procter & Gamble Health Ltd, formerly Merck Ltd, manufactures and markets vitamins, minerals, supplements and other healthcare products under brands including Neurobion, Livogen, Seven Seas, Evion, Polybion and Nasivion. It is part of the US-based P&G Group and operates a plant at Usgaon, Goa
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.